Table 2.
Description of clinical data sets.
| Data set | Description of samples |
|---|---|
| A | HNSCC samples obtained from TCGA (n = 523) |
| B | Non-malignant head and neck samples obtained from TCGA (n = 43) |
| C | Non-malignant samples from different organs* from TCGA Pan-Cancer Atlas |
| D | Matched HNSCC and non-malignant samples from TCGA (n = 43 pairs) |
| E | OSCC from the GEO (GSE52633) (n = 20) |
| F | FFPE OSCC tissue (n = 25) and FFPE non-malignant tissue from the buccal mucosa (n = 5) |
| Analyses | |
| A and B | MiRNA discovery |
| B and C | Tissue specificity* of novel miRNAs |
| D | Differential expression between non-malignant samples and HNSCC |
| A | Association of miRNAs with clinical features |
| A | Survival analysis |
| E | Detection of novel miRNAs in an independent cohort |
| F | Experimental validation of most relevant miRNA by RT-qPCR in FFPE tissues |
HNSCC, head and neck squamous cell carcinoma; TCGA, The Cancer Genome Atlas; OSCC, oral squamous cell carcinoma; FFPE, formalin-fixed paraffin-embedded.
*
bile duct (n = 9), bladder (n = 19), brain (n = 5), cervix (n = 3), colon (n = 9), kidney (n = 71), liver (n = 47), lung (n = 91), pancreas (n = 4), prostate (n = 52), stomach (n = 45), and thyroid (n = 59).